DXRGlobeNewsWireDaxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights: Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026) OAK RIDGE, Tenn.
globenewswire.comRead the article